Challenges for Drug Repurposing in the COVID-19 Pandemic Era
The coronavirus disease (COVID-19) pandemic has affected an estimated 16 million persons and caused 0.6 million deaths worldwide by September 2020. The pandemic has led to a rush to repurpose existing drugs, although the underlying evidence base is of variable quality. The improving knowledge of the...
Main Authors: | Janet Sultana, Salvatore Crisafulli, Flic Gabbay, Elizabeth Lynn, Saad Shakir, Gianluca Trifirò |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-11-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.588654/full |
Similar Items
-
Prospects for repurposing CNS drugs for cancer treatment
by: Mohamed Abdelaleem, et al.
Published: (2019-04-01) -
Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates
by: Joana M. O. Santos, et al.
Published: (2021-10-01) -
Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma
by: Michele Persico, et al.
Published: (2022-01-01) -
Repurposing Drugs to Treat Heart and Brain Illness
by: Maranda S. Cantrell, et al.
Published: (2021-06-01) -
“Hard” Drug Repurposing for Precision Oncology: The Missing Link?
by: Pan Pantziarka, et al.
Published: (2018-06-01)